Edinburgh, UK, 08 June 2022 – RoslinCT - a cell and gene therapy/ATMP CDMO, developing life-changing cell and gene therapies in Edinburgh’s BioQuarter– signs lease for 1,453 sqm additional space at Charles Darwin House at the Edinburgh Technopole.
The additional space will include fully fitted Process Development labs and offices to further support RoslinCT’s growth plans. The Process Development lab space (511m2) gives the company expanded capabilities not only for pluripotent cell processing and genome editing but also on viral cell modification and greater scale up/scale out of cell therapy manufacturing processes and will allow the further expansion of the business. The fit-out of the new space has been completed and has already welcomed the RoslinCT Process Development team.
The brand-new office space further supports the company’s rapid growth and provides ample space for 20+ team members to continue offering bespoke cell and gene therapy services to clients worldwide.
Last year, the company introduced its brand-new state-of-the-art cell and gene therapy manufacturing facility and more than doubled its headcount in 2021.
“Continuing our rapid growth, I am very pleased with the expansion of our operations to Edinburgh Technopole.”, says Peter Coleman, CEO of RoslinCT. “This new location provides us with the opportunity to further expand our Process Development capacity and capabilities and meet the growing needs of our sector."
Located in the heart of the Midlothian Science Zone innovation cluster to the south of Edinburgh, Technopole offers a high-quality mix of flexible offices, high specification laboratories and product development space, with good car parking and support services plus, excellent transport links to Edinburgh city centre and Edinburgh Airport.
Simon Hoad, Executive Director of We Are Pioneer Group, said: “We are delighted to welcome RoslinCT to Edinburgh Technopole. We continue to invest in infrastructure and support and, we look forward to working with the team on their future business growth”.
Notes to editors:
- RoslinCT’s new cell and gene therapy manufacturing facility, The BioCube, was formally opened in October by chairman Ian McCubbin CBE on behalf of Sir Patrick Vallance, the Chief Scientific Adviser to the UK government. For more information, please read the full press release here.
For further information, please contact:
Katerina Tsita at RoslinCT on Katerina.Tsita@roslinct.com or 0131 658 5189
RoslinCT is a leading Contract Development and Manufacturing Organisation (CDMO), offering a range of integrated services from technology transfer, process and assay development to GMP manufacturing, storage, QP certification and batch release of cell-based therapies for clinical trials.
RoslinCT has the vision to lead the field in cell and gene therapy manufacturing and be the global partner of choice, building success on expert knowledge, progressive partnerships and the drive to deliver life-changing cell-based products to patients in need. This together with a passion for innovation and a flexible and personalised approach enables RoslinCT to engage with leading cell and gene therapy developers and to provide support at every step of the cell therapy development journey.